Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Net Change in Cash · Q2 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$9.29M, compared with $1.85M a year earlier. Trailing-twelve-month net change in cash was -$2.82M.

Context

  • Net change in cash amounted to 484.2% of revenue in FY2025.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near -$9.29M or moves back toward the trailing-twelve-month quarterly average of -$705.45K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.29M-256.3% QoQ
Last fiscal yearSep 2025
-$6.84M-19.1% YoY
LTMMar 2026
-$2.82M-92.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-601.3%——
1 year-19.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(6.84M) USD
Year-over-year change
+19.1%

Net Change in Cash vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 net change in cash of $2.82M is the 5th largest of the 9 companies compared; the peer median is $1.05M.
  • Its year-over-year change of -92.9% is the 7th highest of 9, against a peer median of -37.5%.
  • Net change in cash amounts to 847.0% of revenue for OTLK, versus a peer median of 58.7%.
OTLK Competitors Peer median
Net Change in Cash for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$55.6M -4.2%+24.2%264.8%
EQEquillium, Inc.LTM Mar 2026$46.82M +1495.8%+11.7%—
SPRBSpruce Biosciences, Inc.LTM Mar 2026$28.5M +151.3%——
CUECue Biopharma, Inc.LTM Mar 2026$3.24M +111.6%—9.9%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$2.82M -92.9%—847.0%
OSTXOS Therapies IncorporatedLTM Mar 2026$2.05M -171.5%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$1.17M -72.5%—50.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$942.82K -70.9%+47.2%66.7%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$883K -115.1%-48.7%—
Peer median (excluding OTLK) $1.05M-37.5%+18.0%58.7%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
Deferred Income Tax498.49K0000
Stock-Based Compensation4.89M7.71M5.55M5.39M8.9M
Change in Working Capital(7.08M)(1.68M)4.75M(3.02M)4.86M
Accounts Receivables0000(1.49M)
Inventory0000(3.34M)
Accounts Payables(198.47K)1.3M3.08M1.39M1.67M
Other Working Capital(6.88M)(2.98M)1.67M(4.41M)8.02M
Other Non-Cash Items341.55K3.15M5.66M4.09M1.58T
Operating Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)
Capital Expenditures0000(3)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment6.31M(2.32M)19.77M(4.27K)(3.04M)
Common Stock Issued46.3M62.31M30.02M60.33M48.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.59M(394.15K)(823.89K)044.98T
Financing Cash Flow56.19M59.59M48.97M60.33M44.98M
Effect of Forex Changes00000
Net Change in Cash1.94M2.92M6M(8.46M)(6.84M)
Free Cash Flow(54.25M)(56.67M)(42.97M)(68.79M)(51.83M)

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.